Research Article
The Clinical Application of Combined Ultrasound, Mammography, and Tumor Markers in Screening Breast Cancer among High-Risk Women

Lin Sun,1 Min Qi,2 Xiaomei Cui,3 and Qinghua Song4

1Department of Clinical Laboratory, Yantaishan Hospital, Yantai 264000, China
2Department of Clinical Laboratory, The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250001, China
3Department of Obstetrics, Affiliated Qingdao Central Hospital, Qingdao University, Qingdao 266042, China
4Department of Medical Imaging, Qingdao Women and Children’s Hospital, Qingdao 266034, China

Correspondence should be addressed to Qinghua Song; songqinghua@qdfuer.com.cn

Received 16 June 2022; Revised 30 June 2022; Accepted 5 July 2022; Published 15 July 2022

Academic Editor: Muhammad Asghar

Copyright © 2022 Lin Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In order to explore the clinical application value of color Doppler ultrasound (CDUS), mammography (MAM), and serum tumor marker carbohydrate antigen 153 (CA153) in screening breast cancer (BC) for high-risk women, a total of 38,241 women were surveyed by epidemiological questionnaire on BC high-risk factors. A total of 10,821 cases were screened, accounting for 28.30%. They were randomly divided into US, MAM, and CA153 and combined examination group which has no significant difference in high-risk factors. Breast cancer in high-risk population was screened by CDUS, MAM, and CA153 and combined examination. CA153 was detected by electroluminescence method. The positive detection rate of BC was 360.41/100,000 (39/10,821). The overall difference in the positive detection rate of BC among 10,821 cases in all age groups was statistically significant. The sensitivity and negative predictive value of combined examination were significantly improved compared with each single examination. Combined examination for BC screening can significantly improve the sensitivity of BC early diagnosis and reduce the missed diagnosis rate.

1. Introduction

With the change of people’s lifestyle, living environment, and the increase of living pressure, malignant tumor has become one of the most important diseases endangering the health of Chinese residents. Among them, BC is a common malignant tumor in women. In recent years, its incidence rate is increasing, and the age of onset has gradually become younger, which seriously threatens women’s health [1]. The onset of BC is insidious without nonspecific symptoms at early stage, and most of them lost the best opportunity for treatment when they were found in the middle and late stage [2, 3]. The prognosis of BC is closely related to its early detection. Early detection, early diagnosis, and early treatment are not only related to the individual survival effect of BC patients but also become a major issue affecting the national economy and people’s livelihood [4]. Therefore, it is particularly important to carry out screening of BC high-risk groups.

At present, the CDUS has become the first choice for the female BC screening which can reveal the internal structure and blood flow of breast masses and observe the morphology, boundary, and internal echo of the lesion and has a strong ability to distinguish solid and cystic masses, but small lesions and calcified lesions easily missed diagnosis and misdiagnose [5, 6]. MAM can image the entire breast with a strong sense of integrity and not easy to miss diagnosis, but with a low resolution for tissue density and inability to clearly show the lesions for dense breast lesions, resulting in low sensitivity and specificity for diagnosis [7, 8]. Thus, there are certain limitations in their application alone. In this study, three methods including CDUS, AMA, and
tumor markers were selected to screen BC in high-risk women. Compare the difference between the value of the combined examination and each single examination to provide a basis for better screening of BC in high-risk groups.

2. Research Objects and Methods

2.1. Research Objects. From January 2016 to December 2018, a total of 38,241 women aged 30-70 from 31 communities in our city were selected for screening BC at high risk. CDUS, MAM, and serum tumor marker CA153 single and combined examination methods were used for BC screening.

2.2. High-Risk Population Screening. Community health service centers publicize the significance and importance of carrying out BC screening to residents through free community diagnosis in communities, distributing of brochures, and household publicity. A questionnaire survey was conducted among female residents aged 30-70 years old who voluntarily participated and signed the informed consent form. Based on the "Harvard Cancer Risk Index" [9], a comprehensive assessment system of individual cancer risk suitable for Chinese population was developed through multidisciplinary expert group discussion and consensus. The respondents completed the "Breast Cancer Risk Assessment Questionnaire" by themselves under the guidance or after being questioned by professionally trained investigators. The basic information of the questionnaire included menarche age, menopause age, delivery history, lactation history, family history of BC, history of benign and malignant breast diseases, dietary habits, changes in postmenopausal weight, and history of long-term use of exogenous estrogen. Each factor has a risk score, and the sum scores of all risk factors constitute the risk score. The risk assessment is performed by collecting the filled data information. Risk scores above 30 were considered high-risk groups and participated in this study.

2.3. CDUS Examination and the Criteria. The diagnostic instrument is PHILIPS iU22, and the frequency of the probe is 5-12 MHz. During the inspection, the examinee was asked to take a supine position, raise arms, and place hands behind the head to fully expose the bilateral breasts, supraclavicular fossa, and bilateral axillary areas. Each quadrant of the breast, the supraclavicular fossa, and bilateral axillary regions were scanned. Firstly, the lesion location, morphology, mass size, borders, whether the internal echo is uniform, whether there is attenuation of posterior echo, calcification, and association with surrounding tissues, whether lymph nodes metastasize in axillary and clavicle, and other acoustic images were observed, and then, the shape and distribution of blood flow signals inside and around the lesion were observed, and hemodynamic parameters was also measured [10].

Two-dimensional US images revealed obvious masses which were irregular in shape, blurred in boundary, lobulated, burr-shaped, uneven internal echo and attenuation of the rear echo, and calcification (Figure 1(a)). CDUS showed more abundant blood flow in and around the mass (Figure 1(b)).

2.4. Mammography Examination and the Criteria. MAM was performed by a diagnostic instrument GE Senographe 2000D digital MAM machine. In general, internal and external oblique (MLO) and axial (CC) positions were used for photography, and magnification photography or compression photography with small compressors was used for small lesions. The X-ray differential diagnosis of benign and malignant breast diseases is mainly performed from the density, morphology, and indirect signs of the mass. The diagnostic criteria refer to the BI-RADS classification standard (Breast Imaging Reporting and Data System of the American College of Radiology) [11].

MAM examination showed the presence of masses or nodules with irregular, blurred borders, lobular and burr-like changes, micro, granular, or cast calcifications, localized dense infiltration, or skin changes (Figure 2).

2.5. Detection of Serum Tumor Marker CA153. Serum tumor marker CA153 was detected by ELEcsys-2010 (Roche, Suisse) using electroluminescence method. All operations were carried out strictly according to the operating instructions, and the quality control met the requirements. The normal reference values of tumor markers is CA153 < 25.00 U/ml. Serum CA153 > 25.00 U/ml was diagnosed as positive.
2.6. The Criteria for Combined Examination. In the combined examination, one or more of the positives were judged as positive, and all were negative to judge to be negative.

2.7. Statistical Analysis. The data were processed by SPSS 25.0 statistical software. Data were expressed as mean ± standard deviation ($x \pm s d$). The comparison of means between groups was performed by analysis of variance, and the comparison of count data was performed by the $\chi^2$ test. $P < 0.05$ was statistically significant.

3. Results

3.1. Screening Results for High-Risk BC Populations. A questionnaire survey of BC risk factors and assessment of high-risk groups were conducted on 38,241 women. A total of 10,821 eligible people were screened, accounting for 28.30% (10,821/38,241) with an average age of 52 ± 10.21 years. They were randomly divided into US group (2705 cases), MAM group (2707 cases), CA153 group (2703 cases), and combined examination group (2706 cases). There was no statistically significant difference in BC risk factors and comprehensive risk scores among the four groups (Table 1), and they were comparable.

3.2. Comparison of Positive Detection Rates of BC in High-Risk Groups of All Age. With pathological examination as the gold standard, 39 cases of BC were confirmed by pathology in 10,821 cases with the high-risk group. The positive detection rates of the groups aged 30-39, 40-49, and 50-70 were 152.13/100,000 (3/1972), 539.08/100,000 (24/4452), and 272.91/100,000 (12/4397), respectively (Table 2). The overall difference in the positive detection rate of BC among 10,821 cases in the high-risk group in all age was statistically significant ($\chi^2 = 7.277, P = 0.026$) (Table 2). There was a significant difference in the positive detection rate of BC between 40-49 and 30-39 years old ($\chi^2 = 4.889, P = 0.027$) and between 40-49 and 50-70 years old ($\chi^2 = 3.868, P = 0.049$), but there was no significant difference between the ages of 30-39 and 50-70 years ($\chi^2 = 0.845, P = 0.358$) (Table 2).

3.3. Comparison of the Value of CDUS, MAM, and CA153 and Combined Examination in Screening BC among High-Risk Population. A total of 426 of the 10,821 cases were confirmed by pathology, including 39 cases of BC and 387 cases of benign lesions. The results of CDUS, MAM, and CA153 and combined examination were determined to be true positive or true negative if they were consistent with pathological diagnosis, otherwise as false positive or false negative. Compared with each single examination, the sensitivity and negative predictive value of the combined examination were significantly improved (Table 3).

4. Discussion

The pathogenesis of BC is not completely clear. It is currently believed that the occurrence of BC is associated with menarche history, menopause history, long-term use of exogenous estrogen history, menstrual marriage history, BC family history, etc. [12, 13]. Aiming at the high-risk factors of BC, screening high-risk BC populations has great significance for the early diagnosis and early clinical intervention of BC. BC screening includes self-examination, clinician physical examination, imaging examination, and
serum tumor marker examination. Imaging examinations mainly include breast CDUS, MAM, and magnetic resonance imaging (MRI). Imaging examination has been proved to be effective in improving the early diagnosis of BC [14]. MRI is not suitable for BC screening because of its complicated operation and high cost; thus, US and MAM are more suitable for BC screening [15]. In addition, serum tumor marker detection which is an in vitro diagnostic test with the advantages of noninvasive, nonrisk, simple operation, and low cost is often used for BC screening.

The advantages of CDUS are noninvasive, nonrisk, convenient, and free of radiation. It can be suitable for any age, whether pregnant, lactating women, or the elderly, and can be repeated. The patient has good compliance. It has been widely used in clinical BC screening. US can scan the lesion from multiple angles and directions to clearly show the characteristics of the lesion, including position, size, shape, boundary, internal echo, and calcification, and clearly display surrounding tissue of the lesion area to judge the invasiveness of the surrounding tissue [16]. At the same time, according to the characteristics of tumor angiogenesis and blood flow around the lesion, the direction, velocity, and state of blood flow can be analyzed to clearly reflect the information of bleeding flow dynamics and further identify benign or malignant breast mass [17]. US can effectively distinguish cystic lesions from solid lesions [18] and has a strong diagnostic ability for invasive ductal carcinoma, especially for dense breast lesions [19]. The disadvantage of US is that the diagnostic level of the US physician has a large artificial influence on the diagnosis result, it is difficult to find some microcalcification foci and small lesions with unclear echo, and the missed detection rate of ductal carcinoma in situ is high [20, 21].

### Table 1: Comparison of the distribution of high-risk factors among four groups of high-risk BC populations.

| Factors                        | US group \( (n = 2705) \) | MAM group \( (n = 2707) \) | CA153 group \( (n = 2703) \) | Combined detection group \( (n = 2706) \) | \( \chi^2/F \) | \( P \) |
|-------------------------------|-----------------------------|--------------------------------|-----------------------------|---------------------------------------------|----------------|-------|
| Age (years)                   |                             |                                |                             |                                             |                 |       |
| 30-39                         | 485                         | 502                            | 495                         | 490                                         | 3.285           | 0.772 |
| 40-49                         | 1149                        | 1096                           | 1112                        | 1095                                        |                 |       |
| 50-70                         | 1071                        | 1109                           | 1096                        | 1121                                        |                 |       |
| Menarche age (years)          |                             |                                |                             |                                             |                 |       |
| <12                           | 336                         | 295                            | 317                         | 298                                         | 3.984           | 0.263 |
| ≥12                           | 2369                        | 2412                           | 2386                        | 2408                                        |                 |       |
| Menopausal status             |                             |                                |                             |                                             |                 |       |
| Premenopausal                 | 2060                        | 2094                           | 2069                        | 2056                                        | 1.691           | 0.639 |
| Postmenopausal                | 645                         | 613                            | 634                         | 650                                         |                 |       |
| Family history of BC          |                             |                                |                             |                                             |                 |       |
| Yes                           | 180                         | 165                            | 175                         | 170                                         | 0.792           | 0.851 |
| No                            | 2525                        | 2542                           | 2528                        | 2536                                        |                 |       |
| Breast disease history        |                             |                                |                             |                                             |                 |       |
| Yes                           | 157                         | 137                            | 145                         | 150                                         | 1.538           | 0.674 |
| No                            | 2548                        | 2570                           | 2558                        | 2556                                        |                 |       |
| Long-term use of exogenous estrogens |             |                                |                             |                                             |                 |       |
| Yes                           | 39                          | 50                             | 41                          | 35                                          | 2.962           | 0.397 |
| No                            | 2666                        | 2657                           | 2662                        | 2671                                        |                 |       |
| Delivery history              |                             |                                |                             |                                             |                 |       |
| Yes                           | 2545                        | 2562                           | 2561                        | 2568                                        | 2.002           | 0.572 |
| No                            | 160                         | 145                            | 142                         | 138                                         |                 |       |
| Obesity                       |                             |                                |                             |                                             |                 |       |
| Yes                           | 262                         | 252                            | 240                         | 257                                         | 1.210           | 0.751 |
| No                            | 2443                        | 2455                           | 2463                        | 2449                                        |                 |       |
| Risk score \( (x \pm s) \)   | 39.23 ± 6.59                | 37.67 ± 7.12                   | 38.56 ± 6.57                | 39.12 ± 7.01                                | 0.882           | 0.769 |

### Table 2: Comparison of positive detection rates of BC in high-risk groups of all age.

| Group                        | Pathology Positive (n) | Negative (n) | \( \chi^2 \) | \( P \) |
|------------------------------|-----------------------|--------------|--------------|-------|
| 30-39 years \( (n = 1972) \) | 3                     | 1969         | 4.889        | 0.027 |
| 40-49 years \( (n = 4452) \) | 24                    | 4428         | 3.868        | 0.049 |
| 50-70 years \( (n = 4397) \) | 12                    | 4385         | 0.845        | 0.358 |

The advantages of CDUS are noninvasive, nonrisk, convenient, and free of radiation. It can be suitable for any age, whether pregnant, lactating women, or the elderly, and can be repeated. The patient has good compliance. It has been widely used in clinical BC screening. US can scan the lesion from multiple angles and directions to clearly show the characteristics of the lesion, including position, size, shape, boundary, internal echo, and calcification, and clearly display surrounding tissue of the lesion area to judge the invasiveness of the surrounding tissue [16]. At the same time, according to the characteristics of tumor angiogenesis and blood flow around the lesion, the direction, velocity, and state of blood flow can be analyzed to clearly reflect the information of bleeding flow dynamics and further identify benign or malignant breast mass [17]. US can effectively distinguish cystic lesions from solid lesions [18] and has a strong diagnostic ability for invasive ductal carcinoma, especially for dense breast lesions [19]. The disadvantage of US is that the diagnostic level of the US physician has a large artificial influence on the diagnosis result, it is difficult to find some microcalcification foci and small lesions with unclear echo, and the missed detection rate of ductal carcinoma in situ is high [20, 21].
MAM is also one of the main methods of BC screening. The advantage is that the entire breast can be imaged, the overall sense is strong, and it is not easy to miss the diagnosis. Smaller lesions, calcification of the lesions (especially microcalcifications), and glares are clearly shown. It has extremely high clinical diagnostic value for ductal carcinoma in situ which is easy to be missed by US, effectively reducing nerve diagnosis and misdiagnosis. In addition, the MAM examination can transmit the image data in digital form to meet the needs of remote consultation. It is an irreplaceable examination method for BC screening, especially for the diagnosis of tumors with malignant calcification. The disadvantages are that the resolution of tissue density is low and the lesions of dense breast lesions cannot be clearly displayed [7, 8]. Moreover, it is insufficient for the identification of cystic mass and solid mass and the diagnosis of invasive ductal carcinoma. In addition, this test has a large radiation dose and is not suitable for pregnant women, lactating women, and repeated inspections.

Tumor markers are a class of substances secreted by tumor cells or produced by the interaction between tumor and host during the carcinogenesis of tissue cells, including some glycoproteins, hormones, enzymes, and other substances, which can be detected in tissues or peripheral body fluids [22]. Serum tumor markers have gradually become an important means of BC screening, and detecting the level of relevant tumor markers has gradually become an important means of detecting the level of relevant tumor markers has gradually become an important means of BC screening. Therefore, the sensitivity and specificity of serum CA153 alone as a screening program for BC screening are not typical. Therefore, it is a good supplementary experiment for imaging examinations, although this study showed that serum CA153 is not sensitive for screening BC in high-risk populations (44.44%), which is related to early screening. CA153 has not been released into the blood to cause false negatives in early BC. Thus, CA153 is still an essential screening item for BC screening. This study also showed that women aged 40-49 has a high incidence of BC, suggesting that regular medical examinations should be performed to achieve early detection and early treatment.

5. Conclusion

With the increasing incidence of BC, it is necessary to explore its screening model. By screening high-risk groups, early BC can be detected, which can significantly improve the clinical cure rate. US, MAM, and serum CA153 are commonly used screening methods, but the value of a single examination is limited. The combined test can complement and confirm each other, thereby reducing misdiagnosis and maximizing the positive detection rate of BC screening.

Data Availability

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

### Table 3: Comparison of the value of CDUS, MAM, and CA153 and combined examination in screening BC among high-risk population (%).

| Detection indicator | Sensitivity | Specificity | Accuracy | Positive predictive value | Negative predictive value |
|---------------------|-------------|------------|----------|--------------------------|--------------------------|
| US                  | 70.00       | 91.51      | 88.10    | 60.86                    | 94.17                    |
| MAM                 | 66.67       | 90.63      | 86.84    | 57.14                    | 93.55                    |
| CA153               | 44.44       | 89.61      | 81.05    | 50.00                    | 87.34                    |
| Combined examination| 90.91\(^a\) | 91.67      | 91.53    | 68.97                    | 98.02\(^a\)              |

\(^a\)Compared with each single examination, \(P < 0.05\).
Conflicts of Interest

The authors have no conflicts of interest to declare.

References

[1] K. M. Kelly, J. Dean, W. S. Comulada, and S.-J. Lee, “Breast cancer detection using automated whole breast ultrasound and mammography in radiographically dense breasts,” *European Radiology*, vol. 20, no. 3, pp. 734–742, 2010.

[2] Z. Anastasiadi, G. D. Lianos, E. Ignatiadou, H. V. Harissis, and M. Mitsis, “Breast cancer in young women: an overview,” *Updates in Surgery*, vol. 69, no. 3, pp. 313–317, 2017.

[3] C. E. DeSantis, J. Ma, A. Goding Sauer, L. A. Newman, and A. Jemal, “Breast cancer statistics, 2017, racial disparity in mortality by state,” *CA: a Cancer Journal for Clinicians*, vol. 67, no. 6, pp. 439–448, 2017.

[4] C. Printz, “Breast cancer mortality rates decline internationally, with some major exceptions,” *Cancer*, vol. 123, no. 7, p. 1085, 2017.

[5] P. A. Ganz and P. J. Goodwin, “Breast cancer survivorship: where are we today?”, in *In Improving Outcomes for Breast Cancer Survivors*, pp. 1–8, Springer, Cham, 2015.

[6] J. H. Yoon, M. J. Kim, H. S. Lee et al., “Validation of the fifth edition BI-RADS ultrasound lexicon with comparison of fourth and fifth edition diagnostic performance using video clips,” *Ultrasongraphy*, vol. 35, no. 4, pp. 318–326, 2016.

[7] C. M. Checka, J. E. Chun, F. R. Schnabel, J. Lee, and H. Toth, “The relationship of mammographic density and age: implications for breast cancer screening,” *American Journal of Roentgenology*, vol. 198, no. 3, pp. W292–W295, 2012.

[8] M. Zulficar, I. Rozhaly, and M. Rahmah, “Do the majority of Malaysian women have dense breasts on mammograms?,” *Biomedical Imaging and Intervention Journal*, vol. 7, 2011.

[9] G. A. Colditz, K. Atwood, K. Emmons et al., “Harvard report on cancer prevention volume 4: Harvard Cancer Risk Index,” *Cancer Causes & Control*, vol. 11, no. 6, pp. 477–488, 2000.

[10] S. H. Lee, J. Chung, H. Y. Choi et al., “Evaluation of screening US–detected breast masses by combined use of elastography and color Doppler US with B-mode US in women with dense breasts: a multicenter prospective study,” *Radiology*, vol. 285, no. 2, pp. 660–669, 2017.

[11] D. Vanel, “The American College of Radiology (ACR) breast imaging and reporting data system (BI-RADS™): a step towards a universal radiological language?,” *European Journal of Radiology*, vol. 61, no. 2, p. 183, 2007.

[12] R. Jagsi, S. T. Hawley, P. Abrahamse et al., “Impact of adjuvant chemotherapy on long-term employment of survivors of early-stage breast cancer,” *Cancer*, vol. 120, no. 12, pp. 1854–1862, 2014.

[13] L. Chen, Y. Chen, X.-H. Diao et al., “Comparative study of automated breast 3-D ultrasound and handheld B-mode ultrasound for differentiation of benign and malignant breast masses,” *Ultrasound in Medicine & Biology*, vol. 39, no. 10, pp. 1735–1742, 2013.

[14] L. L. Humphrey, M. Helfand, B. K. Chan, and S. H. Woolf, “Breast cancer screening: a summary of the evidence for the U.S. preventive services task force,” *Annals of Internal Medicine*, vol. 137, no. 5_Part_1, pp. 347–360, 2002.

[15] H.-B. Pan, K.-F. Wong, T.-L. Yang et al., “The outcome of a quality-controlled mammography screening program: experience from a population-based study in Taiwan,” *Journal of the Chinese Medical Association*, vol. 77, no. 10, pp. 531–534, 2014.

[16] R. M. Sigrist, J. Liau, A. El Kaffas, M. C. Chammas, and J. K. Willmann, “Ultrasound elastography: review of techniques and clinical applications,” *Theranostics*, vol. 7, no. 5, pp. 1303–1329, 2017.

[17] B. L. Sprague, N. K. Stout, S. T. Hawley, P. Abrahamse et al., “Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts,” *Annals of Internal Medicine*, vol. 162, no. 3, pp. 157–166, 2015.

[18] E. Y. Chae, W. K. Moon, H. H. Kim et al., “Association between ultrasound features and the 21-gene recurrence score assays in patients with oestrogen receptor-positive, HER2-negative, invasive breast cancer,” *PLoS One*, vol. 11, no. 6, p. e0158461, 2016.

[19] M. Štěrba, O. Popelová, J. Lenčo et al., “Proteomic insights into chronic anthracycline cardiotoxicity,” *Journal of Molecular and Cellular Cardiology*, vol. 50, no. 5, pp. 849–862, 2011.

[20] M. S. Bae, M. Seo, K. G. Kim, I.-A. Park, and W. K. Moon, “Quantitative MRI morphology of invasive breast cancer: correlation with immunohistochemical biomarkers and subtypes,” *Acta Radiologica*, vol. 56, no. 3, pp. 269–275, 2015.

[21] Y. Ma, G. Li, J. Li, and W.-d. Ren, “The diagnostic value of superb microvascular imaging (SMI) in detecting blood flow signals of breast lesions: a preliminary study comparing SMI to color Doppler flow imaging,” *Medicine*, vol. 94, no. 36, p. e1502, 2015.

[22] J. W. Choi, B. I. Moon, J. W. Lee, H. J. Kim, Y. Jin, and H. J. Kim, “Use of CA15-3 for screening breast cancer: an antibody-lectin sandwich assay for detecting glycosylation of CA15-3 in sera,” *Oncology Reports*, vol. 40, no. 1, pp. 145–154, 2018.

[23] L. Harris, H. Fritsche, R. Mennel et al., “American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer,” *Journal of Clinical Oncology*, vol. 25, no. 33, pp. 5287–5312, 2007.

[24] S. Tang, L. Wei, Y. Sun et al., “CA153 in breast secretions as a potential molecular marker for diagnosing breast cancer: a meta-analysis,” *PLoS One*, vol. 11, no. 9, p. e0163030, 2016.

[25] M. E. Akbari, H. Haghhighatkhah, M. Shafiee, A. Akbari, M. Bahmanpoor, and M. Khayamzadeh, “Mammography and ultrasonography reports compared with tissue diagnosis—an evidence based study in Iran, 2010,” *Asian Pacific Journal of Cancer Prevention*, vol. 13, no. 5, pp. 1907–1910, 2012.

[26] F.-L. Wang, F. Chen, H. Yin et al., “Effects of age, breast density and volume on breast cancer diagnosis: a retrospective comparison of sensitivity of mammography and ultrasonography in China’s rural areas,” *Asian Pacific Journal of Cancer Prevention*, vol. 14, no. 4, pp. 2277–2282, 2013.

[27] S. Shen, Y. Zhou, Y. Xu et al., “A multi-centre randomised trial comparing ultrasound vs mammography for screening breast cancer in high-risk Chinese women,” *British Journal of Cancer*, vol. 112, no. 6, pp. 998–1004, 2015.

[28] J. Weigert and S. Steenbergen, “The Connecticut experiments second year: ultrasound in the screening of women with dense breasts,” *The Breast Journal*, vol. 21, no. 2, pp. 175–180, 2015.